Device Trial Radar · NCT00417989
Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy
Last checked: Nov 20, 2026Latest source record: May 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
485
Actual
Start
Jan 2007
Primary completion
Dec 2009
Study completion Jun 2010
Sponsor
- Lead sponsor
- Medtronic MiniMed, Inc.Public (MDT)
- Sponsor type
- Industry
- First posted
- Jan 4, 2007
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 7 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Outcomes: Average decrease in A1c from baseline to end of Study Phase (52 weeks) for subjects in the "722 Group" is greater than that for subjects in the "Control (MDI) Group". Secondary Outcomes: Incidence and frequency of severe hypoglycemia; Measure of glycemic variability, Area Under the Curve (AUC); Quality of Life; and Health Economic Outcomes (MRU)
Conditions
- Type 1 Diabetes
Interventions
MiniMed Paradigm REAL-Time SystemDevice
Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in A1c From Baseline to 52 WeeksTime frame: Baseline and 52 weeks
Locations
30 sites in 2 countries. Site status is shown where the registry gives one.
Scripps Institute
La Jolla, California
Children's Hospital of Orange County (CHOC)
Orange, California
Barbara Davis Center, University of Colorado
Boulder, Colorado
27 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.